Overview

Temozolomide, Thalidomide, and Lomustine (TTL) in Melanoma Patients

Status:
Completed
Trial end date:
2012-02-02
Target enrollment:
Participant gender:
Summary
The goal of this clinical research study is to find the highest safe dose of lomustine (CCNU, CeeNUTM) that can be given with temozolomide (TemodarTM) and thalidomide (ThalomidTM) in the treatment of metastatic melanoma that has spread to the brain. The safety and effectiveness of this combination therapy will also be studied.
Phase:
Phase 1
Details
Lead Sponsor:
M.D. Anderson Cancer Center
Collaborator:
Celgene Corporation
Treatments:
Dacarbazine
Lomustine
Temozolomide
Thalidomide